| Vorasidenib in IDH1-or IDH2-mutant low-grade glioma IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ... New England Journal of Medicine 389 (7), 589-601, 2023 | 114 | 2023 |
| Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML MA Sekeres, J Watts, A Radinoff, MA Sangerman, M Cerrano, PF Lopez, ... Leukemia 35 (7), 2119-2124, 2021 | 96 | 2021 |
| The microbiome composition of a man's penis predicts incident bacterial vaginosis in his female sex partner with high accuracy SD Mehta, D Zhao, SJ Green, W Agingu, F Otieno, R Bhaumik, D Bhaumik, ... Frontiers in cellular and infection microbiology 10, 433, 2020 | 53 | 2020 |
| Phase II study of pevonedistat (P)+ azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low … L Ades, JM Watts, A Radinoff, M Arnan, M Cerrano, P Font Lopez, ... Journal of clinical oncology 38 (15_suppl), 7506-7506, 2020 | 21 | 2020 |
| Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced … X Zhou, F Sedarati, DV Faller, D Zhao, HM Faessel, S Chowdhury, ... Investigational New Drugs 39, 488-498, 2021 | 16 | 2021 |
| Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes N Kumar, D Zhao, D Bhaumik, A Sethi, PH Gann BMC cancer 19, 1-14, 2019 | 14 | 2019 |
| INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ... Journal of Clinical Oncology 41 (17_suppl), LBA1-LBA1, 2023 | 5 | 2023 |
| A randomized phase 2 study of pevonedistat, venetoclax, and azacitidine versus venetoclax plus azacitidine in adults with newly diagnosed acute myeloid leukemia (AML) who are … NJ Short, F Sedarati, D Zhao, O Tsukurov, S Friedlander, DV Faller Blood 136, 34-35, 2020 | 3 | 2020 |
| LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE … P Wen, I Mellinghoff, M van den Bent, D Blumenthal, M Touat, K Peters, ... Neuro-Oncology 25 (Supplement_5), v310-v311, 2023 | 2 | 2023 |
| QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2DIFFUSE GLIOMA (INDIGO … K Peters, I Mellinghoff, M van den Bent, D Blumenthal, M Touat, J Clarke, ... Neuro-Oncology 25 (Supplement_5), v254-v255, 2023 | 1 | 2023 |
| CTNI-51. A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2 DIFFUSE GLIOMA (INDIGO … T Cloughesy, I Mellinghoff, M van den Bent, D Blumenthal, M Touat, ... Neuro-Oncology 25 (Supplement_5), v86-v87, 2023 | 1 | 2023 |
| Statistical methods of indirect comparison with real-world data for survival endpoint under non-proportional hazards Z Lin, D Zhao, J Lin, A Ni, J Lin Journal of Biopharmaceutical Statistics 32 (4), 582-599, 2022 | 1 | 2022 |
| Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic … X Zhou, DR Mould, D Zhao, MA Sekeres, L Adès, RT Swords, H Handa, ... Journal of Clinical Oncology 39 (15_suppl), 7042-7042, 2021 | 1 | 2021 |
| DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with … S Park, BM Reilly, T Luger, D Zhao, RJ Fram, AB Dash, R Bejar Blood 136, 29-30, 2020 | 1 | 2020 |
| A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life … K Peters, I Mellinghoff, M Van Den Bent, D Blumenthal, M Touat, J Clarke, ... Neurology 102 (17_supplement_1), 5113, 2024 | | 2024 |
| 498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma D Blumenthal, IK Mellinghoff, MJ van den Bent, M Touat, K Peters, ... Annals of Oncology 34, S391, 2023 | | 2023 |
| JOURNAL MEDICINE IK Mellinghoff, MJ van den Bent, DT Blumenthal, M Touat, KB Peters, ... | | 2023 |
| PEVONEDISTAT (P) PLUS AZACITIDINE (A) VS A ALONE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS): EFFICACY AND SAFETY RESULTS FROM STUDY P-2001 (NCT02610777) V Santini, MA Sekeres, J Watts, A Radinoff, M Arnan, M Cerrano, ... HAEMATOLOGICA 106 (10), 2-3, 2021 | | 2021 |
| MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777) J Watts, M Sekeres, A Radinoff, M Arnan, M Cerrano, PF Lopez, J Zeidner, ... Clinical Lymphoma Myeloma and Leukemia 21, S347-S348, 2021 | | 2021 |
| Pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast acute myelogenous … L Ades, J Watts, A Radinoff, M Arnan Sangerman, M Cerrano, ... BRITISH JOURNAL OF HAEMATOLOGY 193, 6-7, 2021 | | 2021 |
